Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy

Yanyan Lou, Julian A. Marin-Acevedo, Prakash Vishnu, Rami Manochakian, Bhagirathbhai Dholaria, Aixa Soyano, Yan Luo, Yan Zhang, Keith L Knutson

Research output: Contribution to journalArticle

Abstract

Immune checkpoint inhibitors have changed the treatment paradigm for patients with cancer. Though a majority of patients tolerate treatment, some develop hematologic toxicities, including eosinophilia. Eosinophilia has been associated with better responses in some patients with melanoma, but this has not been investigated in non-small-cell lung cancer. We present a case of a woman with metastatic lung adenocarcinoma who developed asymptomatic hypereosinophilia after initiation of nivolumab. Her eosinophil count temporarily decreased after transiently stopping the medication, but increased again after re-initiation. She had a favorable tumor response to therapy. This exemplifies the potential role of eosinophilia as a peripheral, readily available biomarker of favorable response to immunotherapy in patients with lung cancer. Awareness of this manifestation is important.

Original languageEnglish (US)
Pages (from-to)577-584
Number of pages8
JournalImmunotherapy
Volume11
Issue number7
DOIs
StatePublished - May 1 2019

Fingerprint

Non-Small Cell Lung Carcinoma
Eosinophilia
Cell Death
Therapeutics
Eosinophils
Immunotherapy
Melanoma
Lung Neoplasms
Neoplasms
Biomarkers

Keywords

  • biomarker
  • hypereosinophilia
  • immune-related adverse events
  • lung cancer
  • nivolumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy. / Lou, Yanyan; Marin-Acevedo, Julian A.; Vishnu, Prakash; Manochakian, Rami; Dholaria, Bhagirathbhai; Soyano, Aixa; Luo, Yan; Zhang, Yan; Knutson, Keith L.

In: Immunotherapy, Vol. 11, No. 7, 01.05.2019, p. 577-584.

Research output: Contribution to journalArticle

Lou, Yanyan ; Marin-Acevedo, Julian A. ; Vishnu, Prakash ; Manochakian, Rami ; Dholaria, Bhagirathbhai ; Soyano, Aixa ; Luo, Yan ; Zhang, Yan ; Knutson, Keith L. / Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy. In: Immunotherapy. 2019 ; Vol. 11, No. 7. pp. 577-584.
@article{8b1f0ff5b72d4faf860208258568a710,
title = "Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy",
abstract = "Immune checkpoint inhibitors have changed the treatment paradigm for patients with cancer. Though a majority of patients tolerate treatment, some develop hematologic toxicities, including eosinophilia. Eosinophilia has been associated with better responses in some patients with melanoma, but this has not been investigated in non-small-cell lung cancer. We present a case of a woman with metastatic lung adenocarcinoma who developed asymptomatic hypereosinophilia after initiation of nivolumab. Her eosinophil count temporarily decreased after transiently stopping the medication, but increased again after re-initiation. She had a favorable tumor response to therapy. This exemplifies the potential role of eosinophilia as a peripheral, readily available biomarker of favorable response to immunotherapy in patients with lung cancer. Awareness of this manifestation is important.",
keywords = "biomarker, hypereosinophilia, immune-related adverse events, lung cancer, nivolumab",
author = "Yanyan Lou and Marin-Acevedo, {Julian A.} and Prakash Vishnu and Rami Manochakian and Bhagirathbhai Dholaria and Aixa Soyano and Yan Luo and Yan Zhang and Knutson, {Keith L}",
year = "2019",
month = "5",
day = "1",
doi = "10.2217/imt-2018-0128",
language = "English (US)",
volume = "11",
pages = "577--584",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "7",

}

TY - JOUR

T1 - Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy

AU - Lou, Yanyan

AU - Marin-Acevedo, Julian A.

AU - Vishnu, Prakash

AU - Manochakian, Rami

AU - Dholaria, Bhagirathbhai

AU - Soyano, Aixa

AU - Luo, Yan

AU - Zhang, Yan

AU - Knutson, Keith L

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Immune checkpoint inhibitors have changed the treatment paradigm for patients with cancer. Though a majority of patients tolerate treatment, some develop hematologic toxicities, including eosinophilia. Eosinophilia has been associated with better responses in some patients with melanoma, but this has not been investigated in non-small-cell lung cancer. We present a case of a woman with metastatic lung adenocarcinoma who developed asymptomatic hypereosinophilia after initiation of nivolumab. Her eosinophil count temporarily decreased after transiently stopping the medication, but increased again after re-initiation. She had a favorable tumor response to therapy. This exemplifies the potential role of eosinophilia as a peripheral, readily available biomarker of favorable response to immunotherapy in patients with lung cancer. Awareness of this manifestation is important.

AB - Immune checkpoint inhibitors have changed the treatment paradigm for patients with cancer. Though a majority of patients tolerate treatment, some develop hematologic toxicities, including eosinophilia. Eosinophilia has been associated with better responses in some patients with melanoma, but this has not been investigated in non-small-cell lung cancer. We present a case of a woman with metastatic lung adenocarcinoma who developed asymptomatic hypereosinophilia after initiation of nivolumab. Her eosinophil count temporarily decreased after transiently stopping the medication, but increased again after re-initiation. She had a favorable tumor response to therapy. This exemplifies the potential role of eosinophilia as a peripheral, readily available biomarker of favorable response to immunotherapy in patients with lung cancer. Awareness of this manifestation is important.

KW - biomarker

KW - hypereosinophilia

KW - immune-related adverse events

KW - lung cancer

KW - nivolumab

UR - http://www.scopus.com/inward/record.url?scp=85063880366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063880366&partnerID=8YFLogxK

U2 - 10.2217/imt-2018-0128

DO - 10.2217/imt-2018-0128

M3 - Article

VL - 11

SP - 577

EP - 584

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 7

ER -